[Fecal neutrophil gelatinase-associated lipocalin is a surrogate marker of inflammation in inflammatory bowel disease].
OBJECTIVE
To evaluate the fecal level of neutrophil gelatinase-associated lipocalin (NGAL) in different behavior of inflammatory bowel disease (IBD).


METHODS
We prospectively included 41 people into the study--30 patients with active IBD and 11 healthy volunteers. The concentration of NGAL in faeces was determined by enzyme immunoassay method.


RESULTS
Fecal NGAL level was increased in both UC and CD: in CD--5924.27 ± 2067.6 ng/ml (p < 0.05), in UC--5826.09 ± 891.8 ng/ml (p < 0.05) NGAL levels were higher than in the control group (658.8 ± 237.7 ng/ml). Maximal changes were seen in colonic involvement. NGAL levels increased with the increasing extension of lesion in UC (p < 0.05), while in CD concentration was higher in colitis than in ileitis and ileocolitis (p > 0.05) . NGAL level increased with severity of CD (p < 0.05), in patients with UC difference was not significant. In UC NGAL level was increased with increasing extension of lesions (p < 0.05), in CD this pattern was not marked. Correlation NGAL level with some clinical and laboratory indicators in CD was established. Sensitivity of test in evaluation of exacerbation of IBD was 80%, specificity--90.9%, area under the ROC curve (AUC)--0.9, positive predictive value--96%, negative predictive value--62.5%; positive likelihood ratio--8.8 and negative likelihood ratio--0.22.


CONCLUSIONS
The fecal concentration of NGAL significantly increased during IBD. With increasing severity and activity of disease level ofNGAL was increased in CD (p < 0.05). Lipocalin-2 values was higher with the increasing extension of lesions in UC (p < 0.05). There has been established the high diagnostic value of the detection of fecal NGAL as a marker of the active phase of IBD.
O D
OD
Zinkevich
D D
DD
Mukhametova
D I
DI
Abdulganieva
N A
NA
Safina
M O
MO
Koporulina
A Kh
AKh
Odintsova
D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D015415:Biomarkers / Q000032:analysis*; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000378:metabolism; D003424:Crohn Disease / Q000175:diagnosis / Q000378:metabolism; D005243:Feces / Q000737:chemistry*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000378:metabolism; D000071068:Lipocalin-2; D054834:Lipocalins / Q000032:analysis*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D000209:Acute-Phase Proteins; D015415:Biomarkers; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins